Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/8994
Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: awareness warranted for 2017/18 season
Rondy, Marc | Gherasim, Alin ISCIII | Casado, Itziar | Launay, Odile | Rizzo, Caterina | Pitigoi, Daniela | Mickiene, Aukse | Marbus, Sierk D | Machado, Ausenda | Syrjänen, Ritva K | Pem-Novose, Iva | Horváth, Judith Krisztina | Larrauri, Amparo ISCIII | Castilla, Jesús | Vanhems, Philippe | Alfonsi, Valeria | Ivanciuc, Alina E | Kuliese, Monika | van Gageldonk-Lafeber, Rianne | Gomez, Veronica | Ikonen, Niina | Lovric, Zvjezdana | Ferenczi, Annamária | Moren, Alain
Euro Surveill. 2017 Oct;22(41).
In a multicentre European hospital study we measured influenza vaccine effectiveness (IVE) against A(H3N2) in 2016/17. Adjusted IVE was 17% (95% confidence interval (CI): 1 to 31) overall; 25% (95% CI: 2 to 43) among 65-79-year-olds and 13% (95% CI: -15 to 30) among those ≥ 80 years. As the A(H3N2) vaccine component has not changed for 2017/18, physicians and public health experts should be aware that IVE could be low where A(H3N2) viruses predominate.
Adolescent | Adult | Aged | European Union | Female | Hospitalization | Hospitals | Humans | Influenza A Virus, H3N2 Subtype | Influenza Vaccines | Influenza, Human | Male | Middle Aged | Outcome Assessment, Health Care | Seasons
Files in this item